NGEN Latest Press Releases

-- May 26, 2026 --

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study Globe Newswire 7:15 AM

-- May 21, 2026 --

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities Globe Newswire 11:27 PM

NervGen Announces Proposed Public Offering of Securities Globe Newswire 4:01 PM

-- May 18, 2026 --

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 7:15 AM

-- April 27, 2026 --

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer Globe Newswire 7:30 AM

-- April 13, 2026 --

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference Globe Newswire 7:45 AM

-- April 7, 2026 --

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia Globe Newswire 7:30 AM

-- March 31, 2026 --

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates Globe Newswire 7:45 AM

-- March 12, 2026 --

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange Globe Newswire 4:15 PM

-- March 4, 2026 --

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software